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Abstract
Background: Improving lung cancer risk assessment is required because current early-detection screening criteria miss most
cases. We therefore examined the utility for lung cancer risk assessment of a DNA Repair score obtained from OGG1, MPG,
and APE1 blood tests. In addition, we examined the relationship between the level of DNA repair and global gene expression.
Methods: We conducted a blinded case-control study with 150 non–small cell lung cancer case patients and 143 control indi-
viduals. DNA Repair activity was measured in peripheral blood mononuclear cells, and the transcriptome of nasal and bron-
chial cells was determined by RNA sequencing. A combined DNA Repair score was formed using logistic regression, and its
correlation with disease was assessed using cross-validation; correlation of expression to DNA Repair was analyzed using
Gene Ontology enrichment.
Results: DNA Repair score was lower in case patients than in control individuals, regardless of the case’s disease stage.
Individuals at the lowest tertile of DNA Repair score had an increased risk of lung cancer compared to individuals at the highest
tertile, with an odds ratio (OR) of 7.2 (95% confidence interval [CI] ¼ 3.0 to 17.5; P< .001), and independent of smoking. Receiver
operating characteristic analysis yielded an area under the curve of 0.89 (95% CI¼ 0.82 to 0.93). Remarkably, low DNA Repair
score correlated with a broad upregulation of gene expression of immune pathways in patients but not in control individuals.
Conclusions: The DNA Repair score, previously shown to be a lung cancer risk factor in the Israeli population, was validated
in this independent study as a mechanism-based cancer risk biomarker and can substantially improve current lung cancer
risk prediction, assisting prevention and early detection by computed tomography scanning.
Lung cancer is the leading cause of cancer deaths, being respon-
sible for about 156 000 deaths per year in the United States (1,2),
and 388 000 deaths per year in Europe (3). Detection of lung can-
cer at an early stage dramatically increases the 5-year survival
rate from less than 5% at stage IV to 54%–73% at stage I,
highlighting the effectiveness of early detection in reducing
lung cancer mortality (4). Identification of people at high risk for
lung cancer is important for empowering effective early detec-
tion, and currently the main lung cancer risk factors are age and
smoking history (5–9). Indeed, recommendations for computed
tomography (CT) screening for early lung cancer detection in
the United States are based on age and heavy smoking, which
were used in the National Lung Screening Trial (NLST) (10). This
trial showed that CT screening followed by treatment led to a
20% reduction in lung cancer mortality (10), confirmed by the
NELSON trial, which recently showed a 26% reduction in lung
cancer mortality in men after CT screening and treatment (11),
and consistent with the earlier single-arm I-ELCAP study (12). If
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the NLST selection criteria were to be applied to all eligible indi-
viduals in the United States, estimations show that only 27% of
lung cancer case patients would be detected (13). Although this
is a substantial proportion, it does suggest that additional risk
factors await discovery and employment.
Because DNA repair is crucial for removing DNA damage and
avoiding mutations (14–16), suboptimal DNA repair is likely to
cause cancer risk. This is clearly illustrated in the extreme cases
of germline mutations in DNA Repair genes, which cause repair
deficiency and high predisposition to cancer (17–19). Similarly,
suboptimal DNA Repair activity was reported to be associated
with cancer risk for a variety of DNA Repair mechanisms and
cancer types (20–25).
Here we examined, in a blinded, case-control study, whether
a low DNA Repair score, calculated from the DNA Repair enzy-
matic activities of OGG1 (8-oxoguanine DNA glycosylase), MPG
(methylpurine DNA glycosylase), and APE1 (apurinic/apyrimidinic
endonuclease 1) (also known as OMA score), all of which act pri-
marily on oxidative DNA damage, is a risk biomarker for lung
cancer in the United Kingdom as it was in the Israeli population
(23,25–27). In addition, we examined whether variation in the
DNA Repair score measured in peripheral blood mononuclear
cells (PBMC) correlates with systematic effects on gene expression
in airway cells of lung cancer patients and control individuals.
Methods
Study Participants
Patients at least age 18 years referred to Royal Papworth Hospital,
Cambridge, Thoracic Oncology service for investigation of sus-
pected lung cancer were recruited between October 2013 and
November 2015. Those with a history of previous lower or upper
airway cancer were excluded, as were patients with symptoms
who were initially recruited to the study but later were found to
have no evidence of cancer. Control individuals were healthy vol-
unteers recruited from the Cambridge BioResource, a panel of ap-
proximately 17 600 volunteers, both with and without health
conditions, who are willing to be approached to participate in re-
search studies (https://www.cambridgebioresource.group.cam.ac.
uk). They were selected in an attempt to form a sex and age com-
position comparable to the cases group. Disease stage was
reported according to the seventh edition of the tumor, lymph
node, metastasis (TNM) classification of malignant tumors (28).
Research ethics approvals for sample collection from participants
in this study were given by East of England Cambridge Central
REC 13/EE/0012 and the National Research Ethics Service
Committee South East Coast – Surrey 13/LO/0889. Table 1 summa-
rizes the characteristics of case patients and control individuals.
Specimens, Protein Extracts, DNA Repair Assays, and
RNA Sequencing
Each participant donated 17 mL blood (two 8.5 mL ACD vacu-
tainers) from which, within 2–4 hours, PBMC were isolated by
Ficoll fractionation and frozen as previously described (23,29).
Protein extracts, DNA substrates, and DNA Repair assays were
performed as previously described (24,25,30,31) and are briefly
described in the Supplementary Methods (available online). The
outline of the DNA Repair assays is described in Figure 1.
Bronchial and nasal sample collection, along with RNA extrac-
tion, sequencing, and analysis, are described in the
Supplementary Methods (available online).
Statistical Analysis
Personal characteristics of case patients and control individuals
were compared using unpaired t tests for continuous variables
and v2 tests for categorical variables. The smoking status distri-
bution differed between case patients and control individuals,
with approximately 30% of the control individuals being never
smokers compared to only one case patient. In addition,
whereas case patients and control subjects were quite well-
matched by sex, the control individuals were approximately 9
years younger than the case patients on average. Therefore, all
comparisons of case patients and control individuals were ad-
justed for smoking and age, as well as sex. The adjustment was
performed by using regression models in which these factors
were included as covariates. Because of the large imbalance in
the smoking variable, these regression analyses essentially com-
pare the 98 ever-smoked control individuals with the 149 ever-
smoked case patients, and little information is gained from the
never-smokers. Indeed, in additional analyses where we ex-
cluded the never-smokers, the regression results were virtually
unchanged from those reported in Results. Chronic obstructive
pulmonary disease (COPD) was reported more commonly among
the lung cancer case patients than among the control individu-
als; no adjustment for COPD was made in our analyses because
it is likely a mediating factor rather than a confounder in the as-
sociation of DNA Repair enzymes with lung cancer, and adjust-
ing for mediating factors is not recommended (32).
The association of enzymatic DNA repair activity levels with
lung cancer risk was evaluated using an unconditional logistic re-
gression model in which the presence or absence of lung cancer
was the binary dependent variable, and the covariates were the
DNA Repair enzyme levels (OGG1, MPG, and APE1) together with
age (continuous), sex, and smoking status (smoker, past smoker,
never smoker) as adjusting variables. From this model, the DNA
Table 1. Characteristics of case patients and control individuals
Characteristics
Control individuals
(N¼ 143)
Case patients
(N¼ 150) P*
Sex, No. (%) .291
Male 79 (55.2) 93 (62.0)
Female 64 (44.8) 57 (38.0)
Age, mean (SD) 59.7 (10.0) 68.669.6 <.001
Smoking status, No. (%) <.001
Current 48 (33.6) 62 (41.3)
Ex-smoker 50 (35.0) 87 (58.0)
Never 45 (31.5) 1 (0.7)
Pack-years, mean (SD) 16.8620.3 43.2627.6 <.001
Histology, No. (%)
Adenocarcinoma — 83 (55.3)
Squamous — 56 (37.3)
NSCLC-NOS — 11 (7.3)
COPD, No. (%) <.001
None 112 (83.6) 56 (41.8)
Mild 9 (6.7) 26 (19.4)
Moderate 10 (7.5) 31 (23.1)
Severe 3 (2.2) 16 (11.9)
Severity unknown 0 (0.0) 5 (3.7)
*P value comparing the distribution of case patients with control individuals: For
categorial values the chi-square test was used; for continuous variables the
unpaired t test was used. COPD ¼ chronic obstructive pulmonary disease; NSCLC-
NOS ¼ non–small cell lung cancer–not otherwise specified; — ¼ not applicable;
Missing values: pack-years: three control individuals; COPD: nine control individu-
als and 16 case patients.
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Repair scores were derived using the estimated regression coeffi-
cients for the OGG1, MPG, and APE1 variables. The resulting for-
mula of the DNA Repair score for each study participant was DNA
Repair score ¼ 0.00621  APE1 – 0.047  OGG1 – 0.0223  MPG.
Examination of the scores for case patients and control individu-
als showed them to be approximately normally distributed
within each group. This score was then entered as a covariate in
a new logistic regression model, either as a continuous variable
or in tertile categories (according to the score distribution in the
control individuals), with the same adjusting variables, to obtain
odds ratio estimates and receiver-operating characteristic (ROC)
curves to describe the strength of the DNA Repair score–lung can-
cer association. The DNA Repair score formula optimized for this
cohort of participants was different from the previous study (25),
most likely because of the revised APE1 assay in this study and
the fact that different cohorts of modest size were used in the
two studies. To overcome the bias arising from use of the same
data to develop the DNA Repair score and evaluate its strength of
association, the odds ratios and ROC curves were reestimated
using “leave-one-out” cross-validation (33). Confidence limits
(bias-correction and acceleration method) for the area under the
curve (AUC) of the ROC and the comparison test of two AUCs
were computed using the nonparametric bootstrap. The continu-
ous scores were also compared with case-control status, age
group (55, 56–69, 70 years), sex, smoking status, and histology
and disease stage (among case patients) using analysis of covari-
ance, in each case adjusting for the other factors (Table 2). A
P value equal to or less than .05 was considered statistically sig-
nificant and all tests were two-sided.
Results
DNA Repair Score in Lung Cancer Patients Compared to
Control Individuals in the United Kingdom
To examine whether a low DNA Repair score is associated with
lung cancer risk in the United Kingdom, we conducted a case-
control study with 150 non–small cell lung cancer case patients
and 143 control individuals for whom we tested the enzymatic
activities for OGG1, MPG, and APE1 in PBMC. Participant ac-
crual, blood collection, and PBMC isolation were performed in
Figure 1. Outline of the panel of DNA Repair assays used to determine the personal DNA Repair score. Each assay measures the activity of a specific DNA Repair en-
zyme, in a protein extract prepared from PBMC, to remove its target DNA damage from a synthetic short oligonucleotide, shown schematically in the upper panel.
Each enzyme assay was run separately under optimized conditions. The target damaged base in each substrate oligonucleotide was 8-oxoguanine in the OGG1 assay
(illustrated by a black circle), hypoxanthine in the MPG assay (orange square), and a furanyl abasic site in the APE1 assay (blue triangle). The asterisks represent a 3’-
Yakima Yellow fluorescence tag. Assays were run on a robotic platform and analyzed in an AB3130XL genetic analyzer. The personal OGG1, MPG, and APE1 enzyme ac-
tivities were then used to calculate the personal DNA Repair score for each participant, as described in Methods. Further description of the DNA Repair assays is pro-
vided in the Supplementary Materials (available online). APE1 ¼ apurinic/apyrimidinic endonuclease 1; MPG ¼ methylpurine DNA glycosylase; OGG1 ¼ 8-oxoguanine
DNA glycosylase; OMA ¼ OGG1, MPG, and APE1; PBMC ¼ peripheral blood mononuclear cells.
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the United Kingdom, after which the PBMC samples were coded
and sent unidentified to Israel to determine their DNA Repair
activities. After completion of DNA Repair testing, the study
was unblinded, and the clinical and DNA Repair data were used
for the statistical analysis. From the logistic regression relating
levels of OGG1, MPG, and APE1 to lung cancer risk (adjusting for
age, sex, and smoking status), the DNA Repair score (defined in
the footnote to Table 2) was derived. Results of the analysis of
this DNA Repair score are presented in Table 2 and Figure 2.
The mean score in patients was 2.67 (95% confidence interval
[CI] ¼ 2.50 to 2.84) and was lower than in the control individu-
als: 4.00 (95% CI ¼ 3.84 to 4.16; P< .001; Table 2). Consistently,
the distribution of DNA Repair score values among patients
was shifted to lower values compared to control individuals
(Figure 2). There were no statistically significant differences be-
tween the mean scores of men and women; individuals with or
without COPD; never, past, and current smokers; and patients
with adenocarcinoma or squamous cell carcinoma (Table 2).
There appeared to be a decrease in DNA Repair score with age
among control individuals, but it did not reach statistical signif-
icance (Table 2).
Association Between Low DNA Repair Score and Lung
Cancer
When the DNA Repair score was assessed as a continuous variable
in relation to lung cancer risk, a 1-SD decrease in the DNA Repair
score was associated with an increased adjusted odds ratio of 2.7
(95% CI¼ 1.9 to 3.7; P< .001), and 2.5 (95% CI¼ 1.8 to 3.4; P< .001) af-
ter cross-validation (Table 3). When the score was categorized into
tertiles, using the tertile with the highest score as reference, the ad-
justed odds ratio for lung cancer in the lowest tertile was 11.5 (95%
CI ¼ 4.3 to 31.2; P< .001), and 7.2 (95% CI ¼ 3.0 to 17.5; P< .001) after
cross-validation (Table 3). These results suggest that a low DNA
Repair score is strongly associated with lung cancer risk.
Patients’ DNA Repair Score by Disease Stage Compared
to Healthy Individuals
The DNA Repair score for case patients was examined within
each disease stage and each TNM category. The mean score in
patients with stage IA lung cancer was 2.95 (95% CI¼ 2.56 to 3.35),
statistically significantly lower than the mean of control
Table 2. Distribution of selected characteristics and DNA Repair score* between non–small cell lung cancer case patients and control individuals
Control individuals (n¼140) Case patients (n¼ 149)
Characteristics No. DNA Repair score mean (95% CI) P No. DNA Repair score mean (95% CI)
All† 140 4.00 (3.84 to 4.16) 149 2.67 (2.50 to 2.84)
PCase vs control‡ < .001
Histology
SQCC – – 56 2.69 (2.45 to 2.93)
Adenocarcinoma – – 82 2.62 (2.38 to 2.86)
Unknown – – 11 2.92 (1.87 to 3.98)
PSQCC vs adenocarcinoma§ ¼ .65
Age, y
55 43 4.28 (3.96 to 4.59) 16 2.36 (1.82 to 2.89)
56–69 75 4.00 (3.81 to 4.20) 64 2.86 (2.55 to 3.16)
70 22 3.45 (2.95 to 3.94) 69 2.56 (2.35 to 2.78)
PAge trendk ¼ .075
Sex
Male 77 3.82 (3.59 to 4.05) 93 2.71 (2.49 to 2.93)
Female 63 4.21 (3.99 to 4.44) 56 2.60 (2.32 to 2.88)
PM vs Fk ¼ .47
Smoking status
Never smoked 45 4.07 (3.79 to 4.36) 1 4.85
Past smoker 49 3.98 (3.72 to 4.24) 87 2.60 (2.40 to 2.81)
Current smoker 46 3.95 (3.62 to 4.27) 61 2.72 (2.43 to 3.02)
PEver-smoked vs never smokedk ¼ .32;
PCurrent smoker vs othersk ¼ .65
COPD
No 109 4.02 (3.85 to 4.19) 56 2.86 (2.55 to 3.18)
Yes 22 3.82 (3.30 to 4.34) 77 2.57 (2.35 to 2.79)
PYes vs no¶ ¼ .13
*The DNA Repair score was defined as: 0.00621  APE1  0.047  OGG1  0.0223  MPG, where APE1, OGG1, and MPG each represent the measured enzyme activity of
an individual. The weights for each component used in the DNA Repair score were calculated from the logistic regression and chosen to optimize strength of associa-
tion of the score with lung cancer for the observed data set. APE1 ¼ apurinic/apyrimidinic endonuclease 1; CI ¼ confidence interval; COPD ¼ chronic obstructive pulmo-
nary disease; MPG ¼ methylpurine DNA glycosylase; OGG1 ¼ 8-oxoguanine DNA glycosylase; SQCC ¼ squamous cell carcinoma.
†Values were missing for three control individuals (two current and one past smoker) and one case patient (current smoker).
‡Two-sided P value comparing the distribution of case patients with control individuals: analysis of covariance was used adjusting the comparison for continuous age,
sex, and smoking status.
§Two-sided P value for comparing SQCC with adenocarcinoma: analysis of covariance was used adjusting for case-control-status, continuous age, sex, and smoking
status.
kTwo-sided P values obtained from analysis of covariance for factor of interest, adjusted for case-control status and other factors from among age, sex, and smoking
status.
¶Two-sided P value comparing COPD vs no COPD; using analysis of covariance adjusting for continuous age and sex.
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individuals (4.00, 95% CI ¼ 3.84 to 4.16; P¼ .0009), adjusted for age,
sex, and smoking status (Figure 3 and Supplementary Table 1,
available online). Within TNM categories, the mean DNA Repair
scores in lung cancer patients with T1A, N0, and M0 were 2.80
(95% CI ¼ 2.35 to 3.25), 2.90 (95% CI¼ 2.64 to 3.17), and 2.76 (95% CI
¼ 2.58 to 2.95), respectively, each statistically significantly lower
than in control subjects (DNA Repair score¼ 4.00), with P values
of .011 for the first, and less than .0001 for the latter two compari-
sons. These findings are consistent with low DNA Repair score
being a risk factor for lung cancer, possibly acting from the early
stages of lung carcinogenesis. The tests performed show a further
small yet statistically significant decline in the DNA Repair score
for more advanced disease stage, N category and M category, and
there is also a statistically nonsignificant decline over T catego-
ries (Supplementary Table 1, available online).
Sensitivity, Specificity, and ROC of DNA Repair Score
Testing
Plotting the sensitivity and specificity of the DNA Repair score
combined with age and smoking status in ROC curves yielded
an AUC of 0.89 (95% CI ¼ 0.82 to 0.93) and 0.88 after cross-
validation (Figure 4B). When DNA Repair score was assessed
separately from age and smoking, the AUC was 0.81 for the DNA
Repair score (0.80 after cross-validation; Figure 4A). The AUC for
age and smoking status without the DNA repair score was 0.83
(95% CI ¼ 0.75 to 0.89) (Figure 4B). The added value of the DNA
Repair score in estimating lung cancer risk on top of the risk
predicted based on age and smoking was statistically significant
(P¼ .0002) and is illustrated by the following sensitivity values:
at a specificity of 95%, the sensitivity of smoking and age as risk
factors is 34%, with the DNA Repair score exhibiting a similar in-
dependent sensitivity of 36%. When the two are combined, the
sensitivity is increased to 54%. Similarly, at a specificity of 90%,
the combined sensitivity is 64%, higher than smoking and age
(43%) or DNA Repair score (50%) risk factors alone.
Correlation Between DNA Repair Score and Expression
of Biological Pathways in Lung Cancer Patients
Having the DNA Repair scores of a group of people, we sought to
examine whether interpersonal variations in DNA repair corre-
late with systemic effects in the human body. To that end, we
examined the relationship between the DNA Repair score and
whole transcriptome RNAseq analysis in airway epithelial cells.
Analysis included 213 participants (92 healthy control
individuals and 121 lung cancer patients) selected after perform-
ing quality control procedures and data cleaning on a larger
RNAseq dataset (see Supplementary Methods, available online).
The correlation between RNA expression levels and DNA Repair
score was tested separately for case patients and control sub-
jects, by regressing the RNA expression levels of each gene in
the dataset on the DNA Repair score values using the DESeq2
tool (34). Sex, age, smoking status, and experimental batch were
incorporated as adjusting variables. Few genes were statistically
significantly correlated with scores at a false discovery rate
threshold of 0.01 (Supplementary Methods, available online).
Hypothesizing that there is a signal in the data that is distrib-
uted over many genes, with small effect size in each gene, we ex-
amined whether there are pathways that are statistically
significantly enriched with varying score values, using Gene Set
Enrichment Analysis (GSEA) (35). For each group (case patients
and control subjects), we ranked approximately 15 000 genes
based on the statistics of DESeq2 and used this ranking as input
to GSEA with default parameters. We tested for overrepresenta-
tion of genes belonging to specific pathways as defined by gene
ontology terms (Supplementary Tables 2 and 3, available online).
Pathways identified by GSEA were manually curated and divided
into three groups: immune system-related pathways, cell cycle
pathways, and other pathways (see keywords in legend to
Supplementary Table 3, available online). The analysis revealed
185 immune response pathways that were statistically signifi-
cantly enriched, spanned by 3154 unique genes negatively corre-
lated with the DNA Repair score. Strikingly, this correlation was
specific for the lung cancer patients and was not observed in the
control individuals’ samples (Figure 5, Supplementary Table 3,
available online). The dramatic enrichment in the immune re-
sponse pathways was robust against subsampling, indicating that
it is not a sampling bias (Supplementary Methods and
Supplementary Figure 3, available online).
Another set of pathways that exhibited negative correlation
with the DNA Repair score represents cell cycle pathways
(Supplementary Table 3, available online). This correlation was
found both in lung cancer patients and control individuals, with
a larger number of pathways enriched in the control partici-
pants. RNAseq analysis of 37 bronchial samples, which were
obtained only from case patients, also showed an enrichment
of immune system–related pathways (Figure 5). In conclusion,
the expression data suggest that low DNA Repair score corre-
lates with broad upregulation of immune response pathways in
lung cancer patients, but not in control individuals.
Discussion
The results presented here indicate that a personal low baseline
DNA Repair score, composed of the enzymatic activities of
OGG1, MPG, and APE1, is a strong risk factor for lung cancer.
Figure 2. DNA Repair score distribution among lung cancer case patients and
control individuals. The frequency distribution of DNA Repair scores is shown
for 149 lung cancer patients (red curve) and 140 control individuals (blue curve).
The graphs were plotted using GraphPad Prism version 5.00 (GraphPad Software,
San Diego, CA), with bin width automatically chosen by the software, with sec-
ond- order smoothing, with two neighbors on each size. Bin width was 0.5 units.
APE1 ¼ apurinic/apyrimidinic endonuclease 1; MPG ¼ methylpurine DNA glyco-
sylase; OGG1 ¼ 8-oxoguanine DNA glycosylase; OMA ¼ OGG1, MPG, and APE1.
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Table 3. Unconditional logistic regression analysis of the DNA Repair score*
Variable Score value
No. of control
individuals (%)
No. of case
patients (%)
Adjusted OR†
(95% CI) P
Cross-validation
Adjusted OR‡ (95% CI) P
Score per 1 SD
decrease§
0.98 U 140 (100.0) 149 (100.0) 2.7 (1.9 to 3.7) <.001 2.5 (1.8 to 3.4) <.001
Score by tertilesk
Highest tertile 4.52 47 (33.6) 6 (4.0) 1.0 (Referent) — 1.0 (Referent) —
Middle tertile 3.68–4.51 46 (32.9) 22 (14.8) 3.0 (1.0 to 8.7) .048 1.6 (0.6 to 4.2) —
Lowest tertile 3.68 47 (33.6) 121 (81.2) 11.5 (4.3 to 31.2) <.001 7.2 (3.0 to 17.5) —
*DNA Repair score definition: 0.00621  APE1 – 0.047  OGG1 – 0.0223  MPG. APE1 ¼ apurinic/apyrimidinic endonuclease 1; CI ¼ confidence interval; MPG ¼ methylpur-
ine DNA glycosylase; OGG1 ¼ 8-oxoguanine DNA glycosylase; OR ¼ odds ratio.
†Unconditional logistic regression adjusted for age, sex, and smoking status (smoker, past smoker, never smoker).
‡Cross-validated odds ratios calculated according to the SDs and tertiles of the cross-validated DNA Repair scores.
§Score was fitted in the unconditional logistic regression model as a continuous variable. 0.98 U is the 1 SD in the control group for the DNA Repair scores. For each
model, the estimated odds ratios for smoking were slightly different and the range was as follows: current vs never ¼ 57.1–59.4; current v ex ¼ 1.27–1.29.
kTertiles of the control individuals’ values. The upper tertile was chosen as the referent.
Figure 3. Analysis of the DNA Repair scores by disease staging. The distributions of the DNA Repair scores are presented for the control individuals (C blue) and for the
lung cancer patients by stage status (in red) using boxplots (whiskers 10th–90th percentile) showing the values lower than the first 10th percentile and greater than the
90th percentile as dots, with the line in the middle plotted at the median. Distributions are presented by disease state (A), T staging (B), N staging (C), and M staging (D).
The number of participants in each subgroup is indicated above the plots. Importantly, the differences between the control groups and each of the earliest stagings in
each category is statistically significant. C vs disease stage IA, P¼ .0009; C vs T1A, P¼ .011; C vs N0, P< .0001; C vs M0, P< .0001. All P values were adjusted for sex, age,
and smoking status. See related numerical values in Supplementary Table 1 (available online), where the means and SDs are presented. The graphs were plotted using
GraphPad Prism version 5.00 (GraphPad Software, San Diego, CA).
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These results validate a previous study performed in an Israeli
population (25) and exhibit comparable estimated relative risk
values (Supplementary Figure 4, available online), suggesting
that low DNA Repair score is a general lung cancer risk factor in
different countries and populations.
Although the studies were retrospective, several lines of evi-
dence suggest that a low DNA Repair score may play a causative
role in lung cancer: DNA Repair score is lower in patients at any
disease staging (overall disease stage and each TNM staging
separately) than in control individuals, including stage I disease,
consistent with low personal baseline DNA repair contributing
to the carcinogenesis process; We have previously compared
DNA Repair activity in blood samples before and after surgery of
non–small cell lung cancer patients and found no correlation
between DNA Repair activity and the presence of the tumor (27);
In a study on the role of low DNA Repair in the risk of head and
neck cancer, we found that DNA Repair activity at diagnosis,
and 3–4 years after treatment and cure, was similar within the
95% confidence interval (26). This suggests that baseline DNA
repair is a personal feature characteristic of an individual and is
not affected by the disease; and the general well-established
role of DNA repair is eliminating DNA damage and avoiding
mutations and cancer (36).
Nevertheless, to definitively prove the causative role of the
DNA Repair biomarker in lung cancer, a prospective study is
needed.
Screening for early detection of lung cancer based on the
NLST criteria (age, heavy smoking) is expected to apply to about
7.5% of all smokers and ex-smokers in the United States and de-
tect about 27% of lung cancers (13). This leaves 92.5% of smokers
and former smokers in the United States and 73% of lung cancer
case patients with no proper risk assessment for early detection
of lung cancer. Our results suggest that adding the DNA Repair
score to the age and smoking considerations is likely to improve
Figure 4. Receiver operating characteristic (ROC) curve of the sensitivity and specificity of the DNA repair score in lung cancer risk and examples of its added value. A)
ROC curve for the DNA repair scores obtained in the current study (black curve) and after cross-validation (red curve). B) ROC curve for the covariates age, sex, and
smoking status (black curve) and after adding the DNA repair score to these basic covariates before (red curve) and after (green curve) cross-validation. C) Estimated
added value of the DNA repair score to lung cancer risk estimates based on the Liverpool Lung Project (LLP) Risk Model. Estimates are presented for a man and a
woman, age 65 years, who are either never smokers or smoked for 30 years. Gray columns represent the 5-year risk according to the Lung Project Risk model. The effect
of having a low DNA repair score of 5th percentile or less (red columns), or a high DNA repair score of 75th percentile or greater (blue columns) are presented. Data
were taken from Supplementary Table 4 (available online). APE1 ¼ apurinic/apyrimidinic endonuclease 1; AUC ¼ area under the curve; CV ¼ cross-validated; F ¼ fe-
male; M ¼ male; MPG ¼ methylpurine DNA glycosylase; OGG1 ¼ 8-oxoguanine DNA glycosylase; OMA ¼ OGG1, MPG, and APE1.
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risk assessment of individuals. For example, using the Liverpool
Lung Project model (see Data Supplements for the calculation,
available online), a male aged 65 years, having smoked for
30 years with no other risk factors, has a projected 1.6% 5-year
risk of developing lung cancer (37). However, assuming the per-
son also has a low DNA Repair score (5th percentile), his risk
increases approximately fourfold to 6.9% (Figure 4C;
Supplementary Table 4, available online). Conversely, if the per-
son had smoked for 50 years, then his projected risk would be
4.5%, but knowing that the person had a relatively high DNA
Repair score (75th percentile), his risk would drop to 1.1%
(Supplementary Table 4, available online). These results illustrate
how using the DNA Repair score could greatly improve lung can-
cer risk assessment, aiding selection of patients for lung cancer
early detection and paving the way to broadening primary and
secondary prevention of lung cancer beyond the NLST criteria.
Aside from the association of low DNA Repair score with lung
cancer risk, we observed a striking correlation between low DNA
Repair score and a broad activation of immune-related pathways
in lung cancer patients, measured by RNAseq gene expression
(Supplementary Tables 2 and 3, available online). The correlation
withstood two types of robustness tests, indicating that the ef-
fect did not occur by chance. Why was such an effect not ob-
served in control individuals? It is possible that activation of the
immune system requires the presence of cancer cells or cells pre-
senting neoantigens, and in addition, the level of DNA repair was
lower in case patients than in control individuals. A low DNA re-
pair might cause a higher mutational burden and an increase in
neoantigens, contributing to the activation of the immune sys-
tem (38,39), similar to the situation in tumors with a mismatch
repair deficiency (40–42). In addition, the tested DNA Repair
enzymes affect the immune system via other mechanisms (43–
47). Because only about 1% of lung cancer case patients exhibit a
mismatch repair deficiency (48,49), a low DNA Repair score might
serve as a biomarker for response to immunotherapy of these
patients, but of course this needs to be directly tested.
The data obtained thus far indicate that DNA Repair score
testing may provide a highly useful risk biomarker that when
combined with smoking history and age can provide effective
risk estimates for lung cancer, beyond the classical smoking his-
tory and age risk factors (Figure 4C). Such risk assessment may
have applications in referring low-dose CT screening to high-risk
individuals who are ineligible under current NLST criteria and
aiding management of indeterminate pulmonary nodules,
assisting prevention, early detection, and therapy of lung cancer.
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